Since inception, Coronado Biosciences has been a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, namely CNDO-201 or Trichuris suis ova (TSO) and CNDO-109. As part of its growth strategy, the Company plans to identify, evaluate and potentially in-license, acquire or invest in pharmaceutical and biotechnology products, technologies and/or companies. Coronado may also from time to time consider financing existing or later-acquired products, technologies or companies through partnerships, joint ventures, direct financings and/or public or private spin-outs.
June 26, 2014:
May 14, 2014:
May 12, 2014:
May 9, 2014:
May 7, 2014:
April 10, 2014:
TSO (Trichuris suis ova or CNDO-201) is a biologic for the treatment of autoimmune diseases.
CNDO-109 is a biologic that activates natural killer (NK) cells for the treatment of acute myeloid leukemia (AML) and solid tumors.
ONGOING CLINICAL TRIALS
Click here for more clinical trial information.